ArticleReumatologia2025
Assessing cardiovascular risk in rheumatoid arthritis patients on Janus kinase inhibitors: real-world data from the European Alliance of Associations for Rheumatology-adapted CUORE risk algorithm.
Article in Reumatologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Janus kinase inhibitors (JAKi) are effective treatments for rheumatoid arthritis (RA), but growing evidence raises cardiovascular (CV) safety concerns. Given the elevated baseline CV risk in RA, appropriate risk stratification is essential. We retrospectively analyzed 116 RA patients treated with JAKi at the University of Naples Federico II (2020-2025), excluding those with previous CV events. Cardiovascular risk was assessed using the CUORE algorithm, adjusted with the European Alliance of Associations for Rheumatology-recommended 1.5 multiplication factor. Patients were stratified into low (37.9%), intermediate (48.3%), and high (13.8%) risk categories. Over a median follow-up of 25.6 months, only one major CV event (myocardial infarction) was recorded, with no CV deaths. Despite the algorithm being developed for the general population, it appears feasible for RA patients on JAKi. Our findings suggest its potential role in guiding CV prevention strategies, although larger, multicenter studies are needed to confirm its predictive value and integrate RA-specific variables.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.